---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-010454"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:53:24.495517+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics reports Q2 net loss of $3.6M, cash $9.4M; raised $100M

## Summary
- Net loss of $3.6M ($1.83/sh) vs loss of $1.1M ($4.00/sh) in Q2 2023.
- R&D expenses $2.3M, up from $0.2M due to Phase 3 LEVEL study costs.
- Cash and equivalents $9.4M at June 30; subsequent private placement raised $100M gross.
- Phase 3 LEVEL study enrolling with 39 investigative sites; patent granted for levosimendan in PH-HFpEF.
- G&A expenses $1.3M vs $1.0M in prior-year quarter.

## SEC filing metadata
- accession: 0001654954-24-010454
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424010454/0001654954-24-010454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424010454/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-010454
- JSON: https://secwatch.observer/filing/0001654954-24-010454.json
- Plain text: https://secwatch.observer/filing/0001654954-24-010454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.